Read + Share
Wang ES, Montesinos P, Minden MD, Lee JH, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed
FLT3mut+ AML ineligible for intensive chemotherapy. Blood 2022;140:1845-1857.
PMID: 35917453
|
 |
|
Wang ES, Montesinos P, Minden MD, Lee JH, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed
FLT3mut+ AML ineligible for intensive chemotherapy. Blood 2022;140:1845-1857.
PMID: 35917453
|
|
|
|